Source-grounded facts extracted from Pacira BioSciences, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Pacira BioSciences, Inc. reported the month of November 2022 results: revenue $57.5 million.
“Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited net product sales of $57.5 million for the month of November 2022.”
Pacira BioSciences, Inc. reported month ended October 31, 2022 results: revenue $54.9 million.
“Pacira BioSciences Reports Preliminary Net Product Sales of $54.9 Million for October 2022”
Pacira BioSciences, Inc. reported the third quarter ended September 30, 2022 results: revenue $167.5 million, net income $0.7 million, or $(0.02) per share (basic and diluted), EPS $(0.02) per share (basic and diluted).
“in such a filing. --- EX-99.1 (EX-99.1) --- FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Reports Third Quarter 2022 Financial Results -- Third quarter revenue of $167 million, increased 31% over prior year -- -- Conference call today at 8:30 a.m. ET -- TAMPA, FL, November 3, 2022 - Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its”
Daryl Gaugler changed role as Chief Operating Officer at Pacira BioSciences, Inc..
“On May 4, 2022, Daryl Gaugler, the current Senior Vice President, Commercial Operations of the Company, was promoted to Chief Operating Officer, effective immediately.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.